JP2024517087A5 - - Google Patents
Info
- Publication number
- JP2024517087A5 JP2024517087A5 JP2023562610A JP2023562610A JP2024517087A5 JP 2024517087 A5 JP2024517087 A5 JP 2024517087A5 JP 2023562610 A JP2023562610 A JP 2023562610A JP 2023562610 A JP2023562610 A JP 2023562610A JP 2024517087 A5 JP2024517087 A5 JP 2024517087A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- weekly
- seq
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163173919P | 2021-04-12 | 2021-04-12 | |
| US63/173,919 | 2021-04-12 | ||
| US202163219155P | 2021-07-07 | 2021-07-07 | |
| US63/219,155 | 2021-07-07 | ||
| US202263266880P | 2022-01-18 | 2022-01-18 | |
| US63/266,880 | 2022-01-18 | ||
| PCT/US2022/024354 WO2022221239A1 (en) | 2021-04-12 | 2022-04-12 | Compositions and methods for treating pediatric myasthenia gravis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024517087A JP2024517087A (ja) | 2024-04-19 |
| JP2024517087A5 true JP2024517087A5 (cg-RX-API-DMAC7.html) | 2025-04-22 |
Family
ID=83640966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023562610A Pending JP2024517087A (ja) | 2021-04-12 | 2022-04-12 | 小児重症筋無力症を治療するための組成物及び方法 |
Country Status (13)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019001806A2 (pt) | 2016-07-29 | 2019-05-07 | Momenta Pharmaceuticals, Inc. | anticorpos para fcrn e métodos de uso dos mesmos |
| EA202190264A1 (ru) | 2018-07-20 | 2021-05-20 | Момента Фармасьютикалз, Инк. | КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101540823B1 (ko) * | 2007-03-30 | 2015-07-30 | 메디뮨 엘엘씨 | 항체 제제 |
| JP6853178B2 (ja) * | 2015-01-30 | 2021-03-31 | モメンタ ファーマシューティカルズ インコーポレイテッド | FcRn抗体およびその使用方法 |
| MA51032A (fr) * | 2017-12-08 | 2021-03-17 | Argenx Bvba | Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée |
| BR112020011310A2 (pt) * | 2017-12-13 | 2020-11-17 | Momenta Pharmaceuticals, Inc. | anticorpos contra fcrn e seus métodos de uso |
| EP3762027A4 (en) * | 2018-02-13 | 2022-06-15 | The Brigham & Women's Hospital, Inc. | THERAPEUTIC FCRN-BASED BISPECIFIC MONOCLONAL ANTIBODIES |
| IL280280B2 (en) * | 2018-07-20 | 2024-11-01 | Momenta Pharmaceuticals Inc | Compositions of fcrn antibodies and methods of use thereof |
| JP7518821B2 (ja) * | 2018-10-16 | 2024-07-18 | ユーシービー バイオファルマ エスアールエル | 重症筋無力症の治療方法 |
-
2022
- 2022-04-12 MX MX2023012032A patent/MX2023012032A/es unknown
- 2022-04-12 BR BR112023021046A patent/BR112023021046A2/pt unknown
- 2022-04-12 CA CA3216642A patent/CA3216642A1/en active Pending
- 2022-04-12 US US18/286,455 patent/US20240182598A1/en active Pending
- 2022-04-12 WO PCT/US2022/024354 patent/WO2022221239A1/en not_active Ceased
- 2022-04-12 KR KR1020237038171A patent/KR20230169207A/ko active Pending
- 2022-04-12 PH PH1/2023/552841A patent/PH12023552841A1/en unknown
- 2022-04-12 JP JP2023562610A patent/JP2024517087A/ja active Pending
- 2022-04-12 AU AU2022256389A patent/AU2022256389A1/en active Pending
- 2022-04-12 IL IL307445A patent/IL307445A/en unknown
- 2022-04-12 EP EP22788750.2A patent/EP4323002A4/en active Pending
-
2023
- 2023-10-11 CL CL2023003033A patent/CL2023003033A1/es unknown
- 2023-10-12 JO JOJO/P/2023/0247A patent/JOP20230247A1/ar unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023548858A5 (cg-RX-API-DMAC7.html) | ||
| Milo | Therapies for multiple sclerosis targeting B cells | |
| CN103930444B (zh) | 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法 | |
| JP2017160208A5 (cg-RX-API-DMAC7.html) | ||
| CN111787981B (zh) | 增加肌肉量和减少脂肪量的方法 | |
| JP2024102205A5 (cg-RX-API-DMAC7.html) | ||
| CN113195540A (zh) | 提供皮下施用抗cd38抗体的方法 | |
| JP2018138551A (ja) | 関節リウマチの治療 | |
| RU2013121156A (ru) | Препарат антитела | |
| JP2022515770A5 (cg-RX-API-DMAC7.html) | ||
| CN115427450A (zh) | 通过施用il-4r拮抗剂治疗特应性皮炎的方法 | |
| CN114344460B (zh) | 含有抗pcsk9抗体的稳定制剂及其制备方法和用途 | |
| CN118105485B (zh) | 一种稳定的抗人IL-4Rα单克隆抗体制剂 | |
| JP2025514142A5 (cg-RX-API-DMAC7.html) | ||
| WO2021100794A1 (ja) | 抗体含有製剤 | |
| EP4387999A1 (en) | Ofatumumab for treating pediatric ms | |
| KR20250110257A (ko) | Hgfr 및 egfr에 특이적으로 결합하는 이중특이성 항체를 포함하는 약학적 조성물 | |
| US20210393777A1 (en) | Stable preparation comprising anti-pcsk9 antibody | |
| US12139546B2 (en) | Methods of treating urea cycle disorders by interfering with glucagon receptor signaling | |
| JP2023531722A5 (cg-RX-API-DMAC7.html) | ||
| JP2022527542A5 (cg-RX-API-DMAC7.html) | ||
| TW202442677A (zh) | 用於治療自體免疫溶血性貧血(aiha)之方法及組成物 | |
| WO2020063668A1 (zh) | 包含抗ox40抗体的制剂、其制备方法及其用途 | |
| TW202404639A (zh) | Aiha之治療 | |
| WO2023134771A1 (zh) | 抗ctla-4抗体药物组合物及其用途 |